NICE recommends Beovu (brolucizumab) for treatment of wet AMD
NICE has issued final guidance recommending Beovu (brolucizumab) to treat wet age-related macular degeneration in adults.
List view / Grid view
NICE has issued final guidance recommending Beovu (brolucizumab) to treat wet age-related macular degeneration in adults.
The EMA’s CHMP has adopted a positive opinion for five medicines and recommended extending the indications for eight more.